Trial Profile

A Phase 1/2 Trial of MRTX849 in Combination With TNO155 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL 2

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adagrasib (Primary) ; Batoprotafib (Primary)
Indications Colorectal cancer; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; Pharmacokinetics
Acronyms KRYSTAL 2
Sponsors Mirati Therapeutics

Most Recent Events

24 Feb 2025 Planned End Date changed from 22 Jan 2025 to 24 Feb 2025.
20 Dec 2024 Planned End Date changed from 24 Dec 2024 to 22 Jan 2025.
13 Jun 2024 Planned End Date changed from 1 Mar 2024 to 24 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com